Login to Your Account



FINANCINGS NEWS
Tracon Pharmaceuticals Inc. raised $27 million for its targeted cancer and ophthalmology therapies with a series B round that added New Enterprise Associates, Biomed Ventures and an undisclosed institutional investor to its global roster of investors, which include Jafco Co. Ltd., Switzerland's Nextech Invest Ltd., Brookline Investments, Arcus Ventures and Japan's BHP – all of whom also participated in the round.

With two more initial public offerings (IPOs) pricing Thursday – a $97.5 million home run by cystic fibrosis player Proqr Therapeutics BV and a $40.2 million infield fly by antibiotics developer Foamix Pharmaceuticals Ltd. – the ups and downs of the IPO market seemed analogous to the set-up for baseball's postseason play.

DUBLIN – Dutch venture capital firm Aglaia has secured $65 million in a first closing of a new oncology fund, which is targeting a final close of $80 million to $100 million.

More FINANCINGS Headlines

Cast Your Vote

Has biotech’s bubble burst?: